查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575043

弓形虫病治疗市场，按类型、按给药途径、按药物类别、按配销通路、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

Toxoplasmosis Treatment Market, By Type, By Route of Administration, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年，弓浆虫病治疗市场规模为31.9032亿美元，2024年至2032年复合年增长率为6.60%。

该市场的驱动因素包括人们对该疾病的认识不断提高、弱势群体患病率不断上升以及药物开发的进步。此外，正在进行的对更有效和更有针对性的疗法的研究预计将塑造市场的未来格局。总体而言，弓形虫病治疗市场在公共卫生中发挥着至关重要的作用，特别是在发病率高的地区。

弓浆虫病治疗市场-市场动态

增加对胎儿发育潜在併发症的了解。

人们对怀孕期间弓形虫病潜在併发症的认识不断提高，已成为弓形虫病治疗市场的重要动力。弓形虫病由寄生虫弓形虫引起，可导致未出生儿童严重问题，包括神经系统问题和发育迟缓。根据美国疾病管制与预防中心 (CDC) 的数据，美国每年出生的婴儿约有 400 至 4,000 名患有先天性弓形虫病，其中 10% 至 15% 可能面临严重的健康併发症。这种不断加深的认识促使医疗保健提供者建议对孕妇进行常规筛检，从而提高了对检测和有效治疗的需求。因此，製药公司越来越积极地开发创新疗法和预防措施，促进市场扩张，以应对这些紧迫的健康问题。

弓形虫病治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 6.60% 左右的复合年增长率成长

根据类型细分，预计先天性弓形虫病将在 2023 年显示最大的市场份额

依给药途径细分，2023年口服为主导类型

根据药物类别细分，乙胺嘧啶是 2023 年的主导类型

按地区划分，北美是 2023 年的主要收入来源

弓形虫病治疗市场-細項分析：

全球弓形虫病治疗市场根据类型、给药途径、药物类别、配销通路和地区进行细分。

市场依类型分为两类：后天性弓浆虫病和先天性弓浆虫病。先天性弓浆虫病是最重要的部位。这种重要性源于对新生儿的关键健康影响以及医疗保健提供者对早期检测和介入的认识的提高。先天性感染可导致严重的神经和眼部併发症，因此有效的治疗至关重要。孕期孕产妇感染发生率的增加进一步强调了有针对性的治疗和预防措施的必要性。因此，研究和开发方面投入了大量资金，重点是改善这个弱势群体的治疗选择。

依药物类别，市场分为五类：乙胺嘧啶、螺旋霉素、甲酰四氢叶酸、磺胺嘧啶、叶酸等。乙胺嘧啶是最重要的药物类别。其重要性源于其作为急性和慢性弓形虫病主要治疗方法的有效性，特别是对于免疫功能低下的患者和症状严重的患者。乙胺嘧啶减少寄生虫负荷的能力及其在联合治疗中的既定用途增强了其在临床实践中的重要性。此外，正在进行的优化其剂量和尽量减少副作用的研究继续巩固其在治疗方案中的主导地位，使其成为治疗弓形虫病的基石。

弓形虫病治疗市场 - 地理洞察

弓形虫病治疗市场最大的地区是北美。由于气候和饲养宠物等因素，该地区的病例数量较多。人们对该疾病的认识不断增强，医疗保健系统不断完善，也推动了市场的发展。许多公司正在开发新的治疗方法和药物来帮助患者。

该地区的研究和开发实力雄厚，可以提供更有效的选择。医疗保健提供者和製药公司之间的合作提高了治疗的可用性。总体而言，北美在弓形虫病治疗市场的成长中发挥关键作用。

弓形虫病治疗市场-竞争格局：

弓形虫病治疗市场的竞争格局由罗氏、赛诺菲和辉瑞等大型製药公司以及创新生物技术公司主导。目前的治疗方案主要包括乙胺嘧啶合併磺胺嘧啶或克林霉素，人们越来越重视新疗法的研发，以解决抗药性并提高疗效。在意识和医疗保健普及的推动下，北美和欧洲的地理成长显着，新兴市场提供了更多机会。

与学术机构和合资企业的合作增强了研发能力，而监管审批流程仍然至关重要。市场趋势向个人化医疗和先进疗法发展，促使公司采取注重产品差异化和竞争性定价的策略。情况是动态的，其特点是创新和应对不断变化的挑战的需要。

最新进展：

2023 年4 月，FDA 批准的药物的计算筛选旨在透过分子对接、稳定性评估和ADMET 分析来识别弓形虫蛋白（如TgDHFR、TgPRS 和TgCDPK1）的潜在抑制剂，然后对有前景的候选药物进行体外验证。

目录

第一章：弓形虫病治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 弓形虫病治疗市场片段（按类型）
    • 依给药途径分類的弓形虫病治疗市场片段
    • 按药物类别分類的弓形虫病治疗市场片段
    • 按配销通路分類的弓形虫病治疗市场片段
    • 弓形虫病治疗市场片段（按国家/地区）
    • 按地区分類的弓形虫病治疗市场片段
  • 竞争洞察

第 3 章：弓形虫病治疗主要市场趋势

  • 弓形虫病治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 弓形虫病治疗市场限制
    • 市场限制影响分析
  • 弓形虫病治疗市场机会
  • 弓形虫病治疗市场未来趋势

第 4 章：弓形虫病治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：弓形虫病治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：弓形虫病治疗市场格局

  • 2023 年弓形虫病治疗市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：弓形虫病治疗市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 后天性弓形虫病
    • 先天性弓浆虫病

第 8 章：弓形虫病治疗市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 注射用
    • 口服

第 9 章：弓形虫病治疗市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 乙胺嘧啶
    • 螺旋霉素
    • 亚叶酸
    • 磺胺嘧啶
    • 叶酸
    • 其他

第 10 章：弓形虫病治疗市场 - 按配销通路

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 11 章：弓形虫病治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美弓形虫病治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲弓形虫病治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区弓形虫病治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲弓形虫病治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲弓形虫病治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 弓浆虫病治疗产业

  • 竞争仪表板
  • 公司简介
    • Roche
    • Sanofi
    • Pfizer
    • Novartis
    • GlaxoSmithKline
    • Bristol-Myers Squibb
    • AbbVie
    • Merck & Co.
    • Teva Pharmaceutical Industries
    • AstraZeneca
    • Gilead Sciences
    • Eisai Co., Ltd.
    • Lundbeck
    • Boehringer Ingelheim
    • Hoffmann-La Roche
    • Amgen

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4045

REPORT HIGHLIGHT

The Toxoplasmosis Treatment Market size was valued at USD 3,190.32 million in 2023, expanding at a CAGR of 6.60% from 2024 to 2032.

The toxoplasmosis treatment market encompasses a range of pharmaceutical products and therapies to manage infections caused by the parasite Toxoplasma gondii. This condition primarily affects immunocompromised individuals, pregnant women, and those with weakened immune systems, making effective treatment critical. Key medications include pyrimethamine, sulfadiazine, and clindamycin, often used in combination to enhance efficacy.

The market is driven by rising awareness of the disease, increasing prevalence in vulnerable populations, and advancements in drug development. Additionally, ongoing research into more effective and targeted therapies is expected to shape the future landscape of the market. Overall, the toxoplasmosis treatment market plays a vital role in public health, particularly in regions with high incidence rates.

Toxoplasmosis Treatment Market- Market Dynamics

Increased understanding of potential complications for fetal development.

The increasing awareness of the potential complications from toxoplasmosis during pregnancy has become a significant driver for the toxoplasmosis treatment market. Toxoplasmosis, caused by the parasite Toxoplasma gondii, can lead to severe issues in unborn children, including neurological problems and developmental delays. According to the Centers for Disease Control and Prevention (CDC), around 400 to 4,000 infants are born annually in the U.S. with congenital toxoplasmosis, with 10% to 15% potentially facing serious health complications. This growing understanding prompts healthcare providers to recommend routine screening for pregnant women, thereby elevating the demand for both testing and effective treatments. As a result, pharmaceutical companies are increasingly motivated to develop innovative therapies and preventive measures, fostering market expansion in response to these pressing health concerns.

Toxoplasmosis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.60% over the forecast period (2024-2032)

Based on Type segmentation, Congenital Toxoplasmosis was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, oral was the leading type in 2023

Based on Drug Class segmentation, Pyrimethamine was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Toxoplasmosis Treatment Market- Segmentation Analysis:

The Global Toxoplasmosis Treatment Market is segmented based on Type, Route of Administration, Drug Class, Distribution Channel, and Region.

The market is divided into two categories based on Type: Acquired Toxoplasmosis and congenital Toxoplasmosis. Congenital Toxoplasmosis is the most significant segment. This prominence arises from the critical health implications for newborns and the heightened awareness among healthcare providers regarding early detection and intervention. Congenital infections can lead to severe neurological and ocular complications, making effective treatment vital. The increasing incidence of maternal infection during pregnancy further emphasizes the need for targeted therapies and preventative measures. As a result, there is substantial investment in research and development focused on improving treatment options for this vulnerable population.

The market is divided into five categories based on Drug Class: Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others. Pyrimethamine is the most significant drug class. Its prominence stems from its effectiveness as a primary treatment for both acute and chronic toxoplasmosis, particularly in immunocompromised patients and those with severe symptoms. Pyrimethamine's ability to reduce the parasite load and its established use in combination therapies enhance its importance in clinical practice. Additionally, the ongoing research into optimizing its dosage and minimizing side effects continues to reinforce its dominant position in treatment protocols, making it a cornerstone in managing Toxoplasmosis.

Toxoplasmosis Treatment Market- Geographical Insights

The largest region in the toxoplasmosis treatment market is North America. This area has a high number of cases due to factors like climate and pet ownership. The growing awareness of the disease and better healthcare systems also boost the market. Many companies are developing new treatments and drugs to help patients.

Research and development in this region are strong, leading to more effective options. Partnerships between healthcare providers and pharmaceutical companies enhance treatment availability. Overall, North America plays a key role in the growth of the toxoplasmosis treatment market.

Toxoplasmosis Treatment Market- Competitive Landscape:

The Toxoplasmosis treatment market features a competitive landscape dominated by major pharmaceutical companies like Roche, Sanofi, and Pfizer, alongside innovative biotech firms. Current treatment options primarily include pyrimethamine combined with sulfadiazine or clindamycin, there is a growing emphasis on research and development for novel therapies to address drug resistance and improve efficacy. Geographic growth is notable in North America and Europe, driven by increased awareness and healthcare access, with emerging markets presenting additional opportunities.

Collaborative efforts with academic institutions and joint ventures enhance R&D capabilities, while regulatory approval processes remain crucial. The market trends towards personalized medicine and advanced therapeutics, prompting companies to adopt strategies focusing on product differentiation and competitive pricing. The landscape is dynamic, characterized by innovation and a need to navigate evolving challenges.

Recent Developments:

In April 2023, Computational screening of FDA-approved drugs aims to identify potential inhibitors of Toxoplasma gondii proteins like TgDHFR, TgPRS, and TgCDPK1 through molecular docking, stability assessments, and ADMET analysis, followed by in vitro validation of promising candidates.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TOXOPLASMOSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Roche
  • Sanofi
  • Pfizer
  • Novartis
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • AbbVie
  • Merck & Co.
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Gilead Sciences
  • Eisai Co., Ltd.
  • Lundbeck
  • Boehringer Ingelheim
  • Hoffmann-La Roche
  • Amgen

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Acquired Toxoplasmosis
  • Congenital Toxoplasmosis

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Parenteral
  • Oral

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Pyrimethamine
  • Spiramycin
  • Leucovorin
  • Sulfadiazine
  • Folic Acid
  • Other

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Toxoplasmosis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Toxoplasmosis Treatment Market Snippet by Type
    • 2.1.2. Toxoplasmosis Treatment Market Snippet by Route of Administration
    • 2.1.3. Toxoplasmosis Treatment Market Snippet by Drug Class
    • 2.1.4. Toxoplasmosis Treatment Market Snippet by Distribution Channel
    • 2.1.5. Toxoplasmosis Treatment Market Snippet by Country
    • 2.1.6. Toxoplasmosis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Toxoplasmosis Treatment Key Market Trends

  • 3.1. Toxoplasmosis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Toxoplasmosis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Toxoplasmosis Treatment Market Opportunities
  • 3.4. Toxoplasmosis Treatment Market Future Trends

4. Toxoplasmosis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Toxoplasmosis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Toxoplasmosis Treatment Market Landscape

  • 6.1. Toxoplasmosis Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Toxoplasmosis Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Acquired Toxoplasmosis
    • 7.1.3. Congenital Toxoplasmosis

8. Toxoplasmosis Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Parenteral
    • 8.1.3. Oral

9. Toxoplasmosis Treatment Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 9.1.2. Pyrimethamine
    • 9.1.3. Spiramycin
    • 9.1.4. Leucovorin
    • 9.1.5. Sulfadiazine
    • 9.1.6. Folic Acid
    • 9.1.7. Other

10. Toxoplasmosis Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Toxoplasmosis Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Toxoplasmosis Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Toxoplasmosis Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Toxoplasmosis Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Toxoplasmosis Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Toxoplasmosis Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Toxoplasmosis Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Roche
    • 12.2.2. Sanofi
    • 12.2.3. Pfizer
    • 12.2.4. Novartis
    • 12.2.5. GlaxoSmithKline
    • 12.2.6. Bristol-Myers Squibb
    • 12.2.7. AbbVie
    • 12.2.8. Merck & Co.
    • 12.2.9. Teva Pharmaceutical Industries
    • 12.2.10. AstraZeneca
    • 12.2.11. Gilead Sciences
    • 12.2.12. Eisai Co., Ltd.
    • 12.2.13. Lundbeck
    • 12.2.14. Boehringer Ingelheim
    • 12.2.15. Hoffmann-La Roche
    • 12.2.16. Amgen

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us